Margo Heath-Chiozzi M.D.
Net Worth

Last updated:

What is Margo Heath-Chiozzi M.D. net worth?

The estimated net worth of Dr. Margo Heath-Chiozzi M.D. is at least $6,351,521 as of 3 Jun 2024. He owns shares worth $275,422 as insider, has earned $3,332,299 from insider trading and has received compensation worth at least $2,743,800 in Celldex Therapeutics, Inc..

What is the salary of Margo Heath-Chiozzi M.D.?

Dr. Margo Heath-Chiozzi M.D. salary is $548,760 per year as Senior Vice President of Regulatory Affairs in Celldex Therapeutics, Inc..

How old is Margo Heath-Chiozzi M.D.?

Dr. Margo Heath-Chiozzi M.D. is 68 years old, born in 1957.

What stocks does Margo Heath-Chiozzi M.D. currently own?

As insider, Dr. Margo Heath-Chiozzi M.D. owns shares in one company:

Company Title Shares Price per share Total value
Celldex Therapeutics, Inc. (CLDX) Senior Vice President of Regulatory Affairs 13,383 $20.58 $275,422

What does Celldex Therapeutics, Inc. do?

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.

CLDX logo
CLDX
Celldex Therapeutics, Inc.
$20.58

Margo Heath-Chiozzi M.D. insider trading

Celldex Therapeutics, Inc.

Dr. Margo Heath-Chiozzi M.D. has made 4 insider trades between 2020-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 58,369 units of CLDX stock on 3 Jun 2024. As of 3 Jun 2024 he still owns at least 13,383 units of CLDX stock.

Transaction Date Security Shares Price per share Total value Source
Option
Incentive Stock Option (Right to Buy) 6,289 $9.02 $56,708
Option
Common Stock 6,289 $9.02 $56,708
Option
Incentive Stock Option (Right to Buy) 58,369 $10.38 $605,870
Option
Common Stock 58,369 $10.38 $605,870
Sale
Common Stock 58,369 $33.65 $1,964,117
Option
Common Stock 2,043 $9.02 $18,422
Option
Common Stock 2,608 $10.38 $27,071
Sale
Common Stock 38,719 $34.07 $1,319,156
Option
Incentive Stock Option (Right to Buy) 2,043 $9.02 $18,422
Option
Common Stock 29,068 $2.78 $80,809
Option
Incentive Stock Option (Right to Buy) 29,068 $2.78 $80,809
Option
Incentive Stock Option (Right to Buy) 2,608 $10.38 $27,071
Option
Common Stock 600 $2.78 $1,668
Option
Incentive Stock Option (Right to Buy) 600 $2.78 $1,668
Sale
Common Stock 600 $40 $24,000
Option
Incentive Stock Option (Right to Buy) 600 $2.78 $1,668
Sale
Common Stock 600 $41.71 $25,026
Option
Common Stock 600 $2.78 $1,668
Option
Incentive Stock Option 10,000 $9.02 $90,170
Option
Common Stock 10,000 $9.02 $90,170
Purchase
Common Stock, par value $0.001 per share 1,000 $3.01 $3,005

Celldex Therapeutics key executives

Celldex Therapeutics, Inc. executives and other stock owners filed with the SEC:

  • Dr. Margo Heath-Chiozzi M.D. (68) Senior Vice President of Regulatory Affairs
  • Dr. Tibor Keler (66) Founder, Chief Scientific Officer & Executive Vice President
  • Mr. Anthony S. Marucci M.B.A. (63) Founder, Pres, Chief Executive Officer & Director
  • Mr. Sam Martin (54) Senior Vice President, Chief Financial Officer, Sec. & Treasurer
  • Ms. Elizabeth Crowley (53) Chief Product Devel. Officer & Senior Vice President